Cytune Pharma
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 12, 2027The maintenance fee for IL-15 and IL-15R\ALPHA Sushi Domain Based Immunocytokines (US 11,753,454) comes due Mar 12, 2027. Unpaid by Sep 13, 2027, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for IL-15 AND IL-15R\alpha SUSHI DOMAIN BASED IMMUNOCYTOKINES (US 10,626,155) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,899,816 | IL-15 and IL-15R\ALPHA Sushi Domain Based Immunocytokines In force · Low confidence | In force | Low confidence | |
| US 10,626,155 | IL-15 AND IL-15R\alpha SUSHI DOMAIN BASED IMMUNOCYTOKINES In force · Medium confidence | In force | Medium confidence | |
| US 11,753,454 | IL-15 and IL-15R\ALPHA Sushi Domain Based Immunocytokines In force · Medium confidence | In force | Medium confidence | |
| US 11,401,312 | Cytokine derived treatment with reduced vascular leak syndrome In force · USPTO record | In force | USPTO record | |
| US 10,808,022 | IL-15/IL-15RALPHA Based Conjugates Purification Method In force · High confidence | In force | High confidence | |
| US 12,060,407 | IL-15/IL-15RALPHA Based Conjugates Purification Method In force · High confidence | In force | High confidence | |
| US 12,661,387 | IL-2/IL-15R Beta Gamma Agonist Dosing Regimens for Treating Cancer or Infectious Diseases In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 1 abandoned · 3 no status recorded
Showing 1 to 10 of 10, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/352,998 | IL-15 and IL-15R\ALPHA Sushi Domain Based Immunocytokines | Jul 14, 2023 | Pending |
| 18/683,180 | IL-2/IL-15RBETAGAMMA Agonist Combination with Antibody-Drug Conjugates for Treating Cancer | Aug 16, 2022 | Pending |
| 17/876,987 | Jul 29, 2022 | No status recorded | |
| 18/573,397 | INTERLEUKIN-15 Based Immunocytokines | Jun 23, 2022 | Pending |
| 17/695,688 | Combined Pharmaceutical Composition | Mar 15, 2022 | Pending |
| 17/693,132 | IL-15 and IL-15RALPHA Sushi Domain Based Modulokines | Mar 11, 2022 | Pending |
| 17/677,589 | Feb 22, 2022 | No status recorded | |
| 18/033,773 | IL-2/IL-15R-BETA-GAMMA Agonist for Treating Squamous Cell Carcinoma | Oct 26, 2021 | Pending |
| 18/033,524 | Oct 26, 2021 | No status recorded | |
| 14/910,491 | Combined Pharmaceutical Composition | Aug 8, 2014 | Abandoned |